256 related articles for article (PubMed ID: 23403635)
1. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.
Martin ES; Belmont PJ; Sinnamon MJ; Richard LG; Yuan J; Coffee EM; Roper J; Lee L; Heidari P; Lunt SY; Goel G; Ji X; Xie Z; Xie T; Lamb J; Weinrich SL; VanArsdale T; Bronson RT; Xavier RJ; Vander Heiden MG; Kan JL; Mahmood U; Hung KE
Clin Cancer Res; 2013 Jun; 19(11):2929-40. PubMed ID: 23403635
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
5. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
6. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Bradshaw-Pierce EL; Pitts TM; Kulikowski G; Selby H; Merz AL; Gustafson DL; Serkova NJ; Eckhardt SG; Weekes CD
PLoS One; 2013; 8(3):e58089. PubMed ID: 23520486
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
9. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
10. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
Mallucci L; Shi DY; Davies D; Jordan P; Nicol A; Lotti L; Mariani-Costantini R; Verginelli F; Wells V; Zicha D
Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
[TBL] [Abstract][Full Text] [Related]
11. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
13. Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.
Belmont PJ; Budinska E; Jiang P; Sinnamon MJ; Coffee E; Roper J; Xie T; Rejto PA; Derkits S; Sansom OJ; Delorenzi M; Tejpar S; Hung KE; Martin ES
Dis Model Mech; 2014 Jun; 7(6):613-23. PubMed ID: 24742783
[TBL] [Abstract][Full Text] [Related]
14. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
15. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
[TBL] [Abstract][Full Text] [Related]
16.
Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
[No Abstract] [Full Text] [Related]
17. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
19. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.
Hung KE; Maricevich MA; Richard LG; Chen WY; Richardson MP; Kunin A; Bronson RT; Mahmood U; Kucherlapati R
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1565-70. PubMed ID: 20080688
[TBL] [Abstract][Full Text] [Related]
20. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
